The global at-home blood collection kits and devices market size was estimated at USD 193.42 million in 2025 and is anticipated to reach USD 381.97 million by 2033, growing at a CAGR of 8.92% from 2026 to 2033. The rising burden of blood-related disorders primarily drives the growth.
The growing emphasis on patient-centric and preventive healthcare, the rapid adoption of telehealth and remote patient monitoring, and the expansion of decentralized clinical trials (DCTs) further support the market expansion. For instance, a study published in the Microchemical Journal in August 2025 highlights that home-based capillary blood testing enables accessible, repeat diagnostics and expands healthcare coverage, especially in underserved populations.
The increasing prevalence of blood-related disorders, such as anemia, Iron Deficiency, Diabetes Mellitus, and Hyperlipidemia, is a primary driver of the global at-home blood collection kits and devices industry. These conditions necessitate frequent diagnostic testing, ongoing monitoring, and early detection with continuous follow-up. For instance, according to the WHO 2025 report, anemia affects approximately 24.3% of the world’s population, or around 1.6 billion people. In 2023, 30.7% of women aged 15-49 and 39.8% of children aged 6-59 months globally were affected by the condition. At-home blood collection solutions effectively address these needs by enabling convenient and repeat sample collection, reducing dependence on hospital visits, improving patient compliance, and supporting timely, data-driven disease management. Furthermore, many blood disorders are chronic and lifelong, necessitating routine hemoglobin checks, platelet monitoring, and coagulation testing, which drives recurring demand for convenient diagnostic solutions. Recent research shows that at-home capillary blood testing improves accessibility, supports repeat diagnostics, enhances patient compliance, and expands healthcare coverage, particularly in underserved populations, strongly promoting the adoption of at-home blood collection devices.
There is a strong global shift toward preventive, patient-centric healthcare, which is driving growth in the at-home blood collection kits and devices market. As patients become more proactive in monitoring their health and detecting conditions early, routine blood testing traditionally performed in clinical laboratories is increasingly being conducted at home. This emphasis on prevention, self-management, and convenience has significantly increased adoption of at-home blood collection devices, enabling regular health checks, early disease detection, and ongoing monitoring without hospital visits. The rising demand for real-time, decentralized diagnostics, particularly for chronic conditions such as diabetes, anemia, and infectious diseases, has reinforced the preference for home-based testing solutions. At-home blood collection devices provide convenience, accessibility, and patient empowerment, supporting preventive care and continuous monitoring while integrating with digital health platforms and remote physician services. For instance, in April 2024, Drawbridge Health’s NanoDrop at-home blood sampling device received FDA 510(k) clearance for over-the-counter use, marking a significant advancement in consumer blood collection technology. NanoDrop’s novel dual nano-lancet design allows individuals to obtain whole-blood samples easily and painlessly at home with the press of a button, greatly enhancing convenience and accessibility for routine health monitoring, chronic disease management, and decentralized clinical research.
The rapid expansion of telehealth services and remote patient monitoring (RPM) is significantly driving the market growth. As healthcare providers increasingly deliver care virtually, the demand for accurate, reliable home-collected blood samples has surged, enabling clinicians to make timely decisions without requiring in-person visits. At-home blood collection kits and devices support this shift by allowing patients to conveniently collect samples at home, which can then be securely transmitted to laboratories or integrated with telehealth platforms for real-time clinical review. These kits often include lancets for finger-prick sampling on specialized cards or advanced, user-friendly on-arm devices, facilitating remote chronic disease monitoring, preventive care, and routine health checks, reducing the need for travel and long wait times. By providing accessible, safe, and easy-to-use solutions, including technologies such as Tasso, RedDrop, and Capitainer SEP10 cards, as well as optional professional phlebotomy services, these devices enhance patient engagement and clinical efficiency. For instance, the American Telemedicine Association’s Home Testing Special Interest Group (SIG), launched in September 2021, aims to accelerate the adoption of home diagnostic testing integrated with virtual care. By promoting home sample collection and advocating supportive telehealth policies, these initiatives underscore how telehealth expansion creates a strong enabling environment for at-home blood collection devices, reflecting broader market momentum toward decentralized, patient-centric healthcare.
The expansion of decentralized clinical trials (DCTs) is a significant growth driver for the at‑home blood collection kits and devices market, as it shifts many trial activities from traditional research sites to participants’ homes or local settings. In DCTs, procedures such as remote monitoring, telemedicine visits, eConsent, and at‑home sample collection reduce patient burden and increase accessibility, enabling broader participation and more representative study populations. These trials help sponsors optimize operational costs, improve recruitment and retention, and accelerate timelines by minimizing the need for frequent clinic visits. Recent market data indicate a sharp increase in DCTs, with decentralized and hybrid designs increasingly employed across therapeutic areas such as diabetes, oncology, and rare diseases. For instance, a 2026 analysis in PLOS Digital Health, reviewing ClinicalTrials.gov, documented the steady rise in decentralized clinical trials. Home sample collection and trial logistics, including the shipping of biological specimens, have grown significantly as part of trial protocols. These developments reinforce the demand for reliable at‑home blood collection kits and devices capable of capturing high-quality samples outside clinical environments to support decentralized study endpoints. As pharmaceutical companies and contract research organizations adopt DCTs more broadly, at-home blood collection technologies are becoming essential infrastructure for remote clinical research, thereby accelerating market acceptance and driving growth.
This product will be delivered within 1-3 business days.
The growing emphasis on patient-centric and preventive healthcare, the rapid adoption of telehealth and remote patient monitoring, and the expansion of decentralized clinical trials (DCTs) further support the market expansion. For instance, a study published in the Microchemical Journal in August 2025 highlights that home-based capillary blood testing enables accessible, repeat diagnostics and expands healthcare coverage, especially in underserved populations.
The increasing prevalence of blood-related disorders, such as anemia, Iron Deficiency, Diabetes Mellitus, and Hyperlipidemia, is a primary driver of the global at-home blood collection kits and devices industry. These conditions necessitate frequent diagnostic testing, ongoing monitoring, and early detection with continuous follow-up. For instance, according to the WHO 2025 report, anemia affects approximately 24.3% of the world’s population, or around 1.6 billion people. In 2023, 30.7% of women aged 15-49 and 39.8% of children aged 6-59 months globally were affected by the condition. At-home blood collection solutions effectively address these needs by enabling convenient and repeat sample collection, reducing dependence on hospital visits, improving patient compliance, and supporting timely, data-driven disease management. Furthermore, many blood disorders are chronic and lifelong, necessitating routine hemoglobin checks, platelet monitoring, and coagulation testing, which drives recurring demand for convenient diagnostic solutions. Recent research shows that at-home capillary blood testing improves accessibility, supports repeat diagnostics, enhances patient compliance, and expands healthcare coverage, particularly in underserved populations, strongly promoting the adoption of at-home blood collection devices.
There is a strong global shift toward preventive, patient-centric healthcare, which is driving growth in the at-home blood collection kits and devices market. As patients become more proactive in monitoring their health and detecting conditions early, routine blood testing traditionally performed in clinical laboratories is increasingly being conducted at home. This emphasis on prevention, self-management, and convenience has significantly increased adoption of at-home blood collection devices, enabling regular health checks, early disease detection, and ongoing monitoring without hospital visits. The rising demand for real-time, decentralized diagnostics, particularly for chronic conditions such as diabetes, anemia, and infectious diseases, has reinforced the preference for home-based testing solutions. At-home blood collection devices provide convenience, accessibility, and patient empowerment, supporting preventive care and continuous monitoring while integrating with digital health platforms and remote physician services. For instance, in April 2024, Drawbridge Health’s NanoDrop at-home blood sampling device received FDA 510(k) clearance for over-the-counter use, marking a significant advancement in consumer blood collection technology. NanoDrop’s novel dual nano-lancet design allows individuals to obtain whole-blood samples easily and painlessly at home with the press of a button, greatly enhancing convenience and accessibility for routine health monitoring, chronic disease management, and decentralized clinical research.
The rapid expansion of telehealth services and remote patient monitoring (RPM) is significantly driving the market growth. As healthcare providers increasingly deliver care virtually, the demand for accurate, reliable home-collected blood samples has surged, enabling clinicians to make timely decisions without requiring in-person visits. At-home blood collection kits and devices support this shift by allowing patients to conveniently collect samples at home, which can then be securely transmitted to laboratories or integrated with telehealth platforms for real-time clinical review. These kits often include lancets for finger-prick sampling on specialized cards or advanced, user-friendly on-arm devices, facilitating remote chronic disease monitoring, preventive care, and routine health checks, reducing the need for travel and long wait times. By providing accessible, safe, and easy-to-use solutions, including technologies such as Tasso, RedDrop, and Capitainer SEP10 cards, as well as optional professional phlebotomy services, these devices enhance patient engagement and clinical efficiency. For instance, the American Telemedicine Association’s Home Testing Special Interest Group (SIG), launched in September 2021, aims to accelerate the adoption of home diagnostic testing integrated with virtual care. By promoting home sample collection and advocating supportive telehealth policies, these initiatives underscore how telehealth expansion creates a strong enabling environment for at-home blood collection devices, reflecting broader market momentum toward decentralized, patient-centric healthcare.
The expansion of decentralized clinical trials (DCTs) is a significant growth driver for the at‑home blood collection kits and devices market, as it shifts many trial activities from traditional research sites to participants’ homes or local settings. In DCTs, procedures such as remote monitoring, telemedicine visits, eConsent, and at‑home sample collection reduce patient burden and increase accessibility, enabling broader participation and more representative study populations. These trials help sponsors optimize operational costs, improve recruitment and retention, and accelerate timelines by minimizing the need for frequent clinic visits. Recent market data indicate a sharp increase in DCTs, with decentralized and hybrid designs increasingly employed across therapeutic areas such as diabetes, oncology, and rare diseases. For instance, a 2026 analysis in PLOS Digital Health, reviewing ClinicalTrials.gov, documented the steady rise in decentralized clinical trials. Home sample collection and trial logistics, including the shipping of biological specimens, have grown significantly as part of trial protocols. These developments reinforce the demand for reliable at‑home blood collection kits and devices capable of capturing high-quality samples outside clinical environments to support decentralized study endpoints. As pharmaceutical companies and contract research organizations adopt DCTs more broadly, at-home blood collection technologies are becoming essential infrastructure for remote clinical research, thereby accelerating market acceptance and driving growth.
Global At-home Blood Collection Kits And Devices Market Report Segmentation
This report forecasts revenue growth at the global, regional & country levels and provides an analysis of industry trends in each sub-segment from 2021 to 2033. For this study, the analyst has segmented the global at-home blood collection kits and devices market report based on product, device type, application, and region:Product Outlook (Revenue, USD Million, 2021-2033)
- Dried Blood Spot (DBS) Kits
- Micro-sampling Devices
- Fingerstick Blood Collection Kits
- Lancets
- Capillary Blood Collection Tubes
- Others
Application Outlook (Revenue, USD Million, 2021-2033)
- Chronic disease monitoring
- Infectious disease testing
- Genetic & hormonal testing
- Preventive health/wellness
Device Type Outlook (Revenue, USD Million, 2021-2033)
- Self-Collection Devices
- Professional-assisted home devices
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. At-home Blood Collection Kits and Devices Market Variables, Trends & Scope
Chapter 4. At-home Blood Collection Kits and Devices Market: Product Estimates & Trend Analysis
Chapter 5. At-home Blood Collection Kits and Devices Market: Application Estimates & Trend Analysis
Chapter 6. At-home Blood Collection Kits and Devices Market: Device Type Estimates & Trend Analysis
Chapter 7. At-home Blood Collection Kits and Devices Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- BD
- Tasso, Inc.
- Trajan Group Holdings Limited
- YourBio Health, Inc.
- Capitainer AB
- A. Menarini Diagnostics
- R-Biopharm AG
- Owen Mumford Ltd
- Spot On Sciences
- RedDrop Dx, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | April 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 193.42 Million |
| Forecasted Market Value ( USD | $ 381.97 Million |
| Compound Annual Growth Rate | 8.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
